BioAge Labs (BIOA) EBT (2023 - 2026)

BioAge Labs (BIOA) has 4 years of EBT data on file, last reported at -$22.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 70.4% year-over-year to -$22.2 million; the trailing twelve-month figure through Mar 2026 stood at -$91.8 million (up 35.39% YoY), and the FY2025 full-year result was -$125.9 million, down 56.33% from the prior year.
• EBT declined to -$22.2 million in Q1 2026, from -$15.5 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$11.8 million in Q3 2023 to a low of -$82.2 million in Q3 2024.
• A 4-year average of -$25.5 million and a median of -$20.3 million in 2023 frame the typical range for EBT.
• Across the five-year window, EBT slumped 597.18% in 2024 and surged 65.27% in 2025, its largest moves.
• Tracing BIOA's EBT over 4 years: stood at -$20.3 million in 2023, then tumbled by 53.59% to -$31.2 million in 2024, then jumped by 50.25% to -$15.5 million in 2025, then slumped by 42.98% to -$22.2 million in 2026.
• Business Quant data shows BIOA's EBT at -$22.2 million in Q1 2026, -$15.5 million in Q4 2025, and -$28.6 million in Q3 2025.